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INTRODUCTION
Pure ovarian choriocarcinomas are extremely rare malignan­
cies which are of gestational or non­gestational in origin. 
The gestational type may arise from an ectopic ovarian pre­
gnancy or present as a metastasis from a uterine or tubal 
choriocarcinoma, while the non­gestational type is a rare 
germ cell tumor with trophoblastic differentiation. The esti­
mated incidence of gestational ovarian choriocarcinomas 
is 1 in 369 million pregnancies [1]. Non­gestational ovarian 
choriocarcinomas account ≤0.6% of all ovarian neoplasms; 
the pure type is extremely uncommon [2]. Due to the 
rarity of pure ovarian choriocarcinomas, information on 
the clinicopathologic features, diagnosis, and therapeutic 
options is limited. Herein we present a case of a pure ovarian 
choriocarcinoma, likely of non­gestational origin, and discuss 
the diagnosis and treatment together with a brief review of 
the literature.
CASE REPORT
A 48­year­old woman was admitted to our department 
with a 6­month history of irregular vaginal bleeding and a 
1­month history of a palpable abdominal mass. She had a 
nor  mal vaginal delivery at 26 years of age and had no recent 
history of normal pregnancies, molar gestations, or abortions. 
The physical examination revealed abdominal tenderness and 
a fixed mass arising from the pelvis to 3 cm below the um­
bilicus. Ultrasound showed a 15­cm solid mass posterior to 
the uterus, and consistent with an ovarian tumor. The serum 
levels of tumor markers, with normal values in parentheses, 
were as follows: β­human chorionic gonadotropin (hCG), 
7,664.3 mIU/mL (<5.0); CA­125, 217.3 U/mL (<35); CA19­9, 18.6 
U/mL (<30); alpha fetoprotein (AFP), 1.9 ng/mL (<20); and car­
cinoembryonic antigen (CEA), 2.5 ng/mL (<5). There was no 
evi  dence of metastasis to other organs. 
After written informed consent was obtained, an exploratory 
laparotomy was undertaken for a suspected ovarian tumor. 
Intra­operatively, a dark­red, soft, friable, 18×15×14 cm mass 
had replaced the right ovary, which was densely adherent 
to the colon, rectum, appendix, and posterior surface of 
the uterus. The left ovary and fallopian tube were normal in 
appearance. There was no ascites within the peritoneal cavity. 
Peritoneal washings were obtained for cytology. Cytoreductive 
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surgery, including a sub­extensive total hysterectomy, bilateral 
salpingo­oophorectomy, pelvic lymphadenectomy, para­aortic 
lymph node sampling, omentectomy, appendectomy, and 
peritoneal biopsies was performed. Optimal debulking was 
achieved with no macroscopic residual tumor. 
Microscopically, the tumor was confirmed to be a pure 
choriocarcinoma with widespread necrosis (Fig. 1). The 
appendi  ceal serosa and peritoneum were identified with 
tumor invasion. The uterus, left ovary, left fallopian tube, 
omentum and all of the extirpated lymph nodes were nega­
tive for malig  nancy. Immunohistochemically, the tumor was 
positive for β­hCG (Fig. 2A) and weakly positive for placental­
like alkaline phosphatase (PLAP) (Fig. 2B). Eighty percent of 
the tumor cells were strongly positive for Ki­67.
Post­operatively, the patient was treated with bleomycin, 
etoposide, and cisplatin (BEP) chemotherapy (etoposide [100 
mg/m
2 on days 1 and 2], cisplatin [20 mg/m
2 on days l­5], and 
bleomycin [30 mg on day 2]) every 28 days. The serum β­hCG 
level decreased to 193.5 mIU/mL 1 week after surgery and was 
within the normal range after 3 cycles of chemotherapy (Fig. 
3). The patient did well after surgery and tolerated 6 cycles of 
chemotherapy without problems and without evidence of 
disease after a 12­month follow­up.
DISCUSSION
Pure ovarian choriocarcinomas are rare, but aggressive tu­
Fig. 2. Supporting immunohistochemistry shows that the tumor is positive for β-human chorionic gonadotropin (A) and weakly positive for 
placental-like alkaline phosphatase (B) (×200).
Fig. 1. Microscopic appearance of the tumor shows a pure choriocar-
cinoma with widespread necrosis (H&E, ×200).
Fig. 3. Decrease in serum β-human chorionic gonadotropin (hCG) 
levels after surgery and combination chemotherapy with etoposide, 
cisplatin and bleomycin. 
#number indicates the cycle number of 
chemotherapy.Pure ovarian choriocarcinoma
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mors that pose diagnostic and therapeutic challenges. The 
pre­operative diagnosis of pure ovarian choriocarcinomas 
is very difficult, especially for patients in the reproductive 
age due to the non­specific clinical symptoms which can 
mimic other more common diseases. In the presence of an 
adnexal mass with an increased serum β­hCG level and 
irregular vaginal bleeding, pure ovarian choriocarcinomas in 
the childbearing age can be easily mistaken for an ectopic 
pregnancy pre­operatively [3,4]. Some authors have reported 
the pre­operative diagnosis of pure ovarian choriocarcinomas 
based on fine needle aspiration cytology [5] or imaging 
and biologic findings [6]. Confirmation of the diagnosis still 
relies on the histopathologic findings. Indeed, the presence 
of malignant cytotrophoblasts and syncytiotrophoblasts, 
immunohistochemical staining with β­hCG, and placental 
lactogen are diagnostic. There are no distinctive ultrastructural 
or immunohistochemical differences between gestational 
and non­gestational choriocarcinomas. Thus, to distinguish 
a gestational ovarian choriocarcinoma from a pure non­
gestational ovarian choriocarcinoma based on conventional 
histopathologic studies is not currently possible in the repro­
ductive age group. Molecular genetic analysis is a reliable 
method for identifying the genetic origin of pure ovarian 
choriocarcinomas [7­10]. However, since such techniques are 
always expensive and not generally available in all medical 
centers, the application is limited. For this very reason, we 
could not perform molecular genetic analysis on the tumor 
from our patient. In light of the long duration (22 years) from 
the antecendent pregnancy, the absence of intrauterine tro­
phoblastic disease, and the relatively low β­hCG level, we 
Table 1. Pure ovarian choriocarcinoma: summary of cases
Authors Age
Gestational or 
non-gestational
β-hCG Surgery Chemotherapy Outcome
Shin et al. [12], 1994 45 Non-gestational 132,005 TAH, BSO MAC 1 yr NED
Byeun et al. [13], 1995 28 Non-gestational 13,378 RSO EMA/CO 1 yr NED
Lorigan et al. [14], 1996 41 Gestational 151,500 TAH, BSO,  
omentectomy
BEP, IE 3 mo NED
Kim et al. [15], 1997 16 Non-gestational 565,000 TAH, BSO MAC Died during 
chemotherapy
Namba et al. [16], 2003 37 Gestational 990,000 RSO, MAC NED
Tsujioka et al. [7] 2003 19 Non-gestational 110,000 LSO, partial omentectomy, 
biopsy of right ovary
EMA/CO NED
Chien et al. [17], 2004 21 Non-gestational 1,787,052.30 LSO, tumor excision EMA/CO Died of sepsis 7 
mo after diagnosis
Balat et al. [3], 2004 24 Non-gestational 8,968 (when admitted)
45,701 (20 days after 
the first operation)
TAH, BSO, infracolic 
omentectomy, pelvic 
lymphadenectomy
BEP Died of disease 
after the 1
st cycle 
of chemotherapy
Bazot et al. [6], 2004 38 Non-gestational 2,460,000 TAH, BSO Yes, details NS 7 yr NED
Koo et al. [9], 2006 33 Non-gestational 185,000 AH, BSO, omentectomy, 
pelvic lymphadenectomy
MAC NED
Gerson et al. [18], 2007 33 Gestational 564,000 TAH, RSO, LS, splenectomy EMA/CO 1 yr NED
Yamamoto et al. [10], 
2007
19 Non-gestational 206,949 LO EMA/CO 12 mo NED
Mood et al. [19], 2009 31 Gestational More than 1000 RSO EMA/CE 7 yr NED
Mood et al. [19], 2009 32 Gestational 5,500 TAH, BSO, tumor
debulkation and infracolic 
omentectomy
BEP, EMA/CE 5 yr NED
Mishra and Crasta [20], 
2008
25 Non-gestational More than 1,000,000 TAH, BSO, omental biopsy Yes, one cycle, 
details NS
Lost follow-up
Park et al. [21], 2009 55 Non-gestational 64,838 TAH, BSO, multiple 
biopsies
BEP 20 mo NED
Gon et al. [22], 2010 21 Non-gestational 279,000 RSO NS NS
hCG, human chorionic gonadotropin; TAH, total abdominal hysterectomy; R, right; L, left; B, bilateral; S, salpingectomy; O, oophorectomy; 
MAC, methotrexate, actinomycin-D, cyclophosphamide; EMA/CO, etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine; 
BEP, bleomycin, etoposide, cisplatin; IE, ifosfamide, etoposide; EMA/CE, etoposide, methotrexate, actinomycin-D, cisplatin, etoposide; NED, no 
evidence of disease; NS, not stated.Lin Lv, et al.
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suggest that our patient had a pure non­gestational ovarian 
choriocarcinoma. 
We have reviewed the previously reported cases of pure 
ovarian choriocarcinoma and summarized the details of 
these cases including β­hCG level, operation procedures, 
chemotherapy and outcome. Since Goswami et al. [11] made 
a detailed summary and analysis about 30 cases of pure 
non­gestational choriocarcinoma in 2001, we only present 
cases not mentioned by Goswami et al. [11] or reported 
after Goswami’s study in our article (Table 1). Accor  ding 
to the previous reports, it seems that pure ovarian chorio­
carcinoma responds well to the combination of surgical 
ablation and post­operative chemotherapy. To date, no 
definitive treatment modality has been established for pure 
ovarian choriocarcinomas due to the low incidence. Thus, 
pure ovarian choriocarcinomas are generally treated by 
the same protocols used for ovarian germ­cell tumors and 
gestational trophoblastic disease. In the current case, the 
treatment included cytoreductive surgery followed by post­
operative chemotherapy. Optimal cytoreductive surgery was 
indispensible in our patient, as demonstrated by the dra­
matic decline in the serum β­hCG level post­operatively. 
There is no consensus on the optimal chemotherapy follow­
ing surgery. Non­gestational ovarian choriocarcinoma has 
been found to have a worse prognosis and requires more 
aggressive chemotherapy compared with gestational 
ovarian choriocarcinoma. Gestational choriocarcinoma 
usually responds well to methotrexate­based chemotherapy; 
however, non­gestational choriocarcinoma may be resistant 
to this therapy [11]. Because non­gestational choriocarcinoma 
is considered as a germ cell tumor differentiating to tropho­
blastic components, a germ cell tumor treatment protocol 
may be effective [3,21]. BEP chemotherapy is the current regi­
men for germ cell tumors of the ovary [23]. Thus, our patient 
underwent BEP chemotherapy for a presumed primary pure 
non­gestational choriocarcinoma. The patient had a good 
response to the BEP regimen with a satisfactory decrease in 
the serum β­hCG level. There was no evidence of recurrence 
or metastasis after a 12­month follow­up. Our case provides 
evidence that cytoreductive surgery in combination with post­ 
operative chemotherapy may be an effective therapeutic 
strategy for pure ovarian choriocarcinomas. Considering that 
pure ovarian choriocarcinoma is aggressive with a high risk of 
metastasis, close follow­up with serum β­hCG and imaging 
examinations is essential.
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